RESEARCH TRIANGLE PARK, N.C., Nov. 2 /PRNewswire-FirstCall/ --
Biotechnology company Icoria, Inc. (OTC Bulletin Board: ICOR.OB) today
announced that on November 14 it will report its 2005 third quarter financial
results for the period ending September 30, 2005.
The company's management team will conduct a conference call and webcast
to discuss the results on Tuesday, November 15, at 8:30 a.m. ET. Interested
participants should call 1-800-231-9012 or, for those calling internationally,
1-719-457-2617. The conference call ID number is 2030345. Icoria encourages
participants to dial in 10 minutes before the call commences.
The webcast can be accessed from Icoria's web site at
http://www.icoria.com by clicking on the Investor Relations link. For those
unable to participate, replays of the call may be heard online at
http://www.icoria.com. Supplemental information will also be available
online.
About Icoria
On September 20, 2005, Icoria announced that it had executed a merger
agreement with Clinical Data Inc. (Nasdaq: CLDA) whereby Clinical Data will
acquire Icoria in an all-stock transaction valued at up to $12.5 million. The
acquisition is expected to close late this year or in early 2006, pending
approval by Icoria's shareholders. More information on this transaction is
available at http://www.icoria.com. More information on Clinical Data is available
at http://www.clda.com.
Icoria, Inc. is a biotechnology company focused on the discovery of novel,
multi-parameter biomarkers using its unique multi-platform approach. Icoria
intends to use these future biomarkers internally to develop multi-analyte
diagnostics to define and grade pathology or disease state with a high level
of specificity and sensitivity, and use its technology to help collaborators
and customers develop better, safer drugs and diagnostics and to identify
targets, leads and drug/diagnostic combinations for liver injury, metabolic
disorders and cancer. Icoria's shares trade on the over the counter bulletin
board.
This press release contains forward-looking statements including, but not
limited to, Icoria's acquisition by Clinical Data, Inc., the Company's
expectations for its healthcare based business model and its biomarker
discovery platform. Such forward-looking statements are based on management's
current expectations and are subject to a number of risks, factors and
uncertainties that may cause actual results, events and performance to differ
materially from those referred to in the forward-looking statements. These
risks, factors and uncertainties include, but are not limited to, Icoria's
ability to identify biomarkers, early stage of development, history of net
losses, technological and product development uncertainties, reliance on
research collaborations, uncertainty of additional funding and ability to
protect its patents and proprietary rights. Certain of these and other risks
are identified in Icoria's Quarterly Reports on Form 10-Q for the period ended
June 30, 2005, as amended, and its Annual Report on Form 10-K for the year
ended December 31, 2004, both as filed with the Securities and Exchange
Commission. The Company does not intend to update any of the forward-looking
statements after the date of this release to conform these statements to
actual results or to changes in our expectations, except as may be required by
law.
SOURCE Icoria, Inc.
 back to top
Related links:
http://www.icoria.com
http://www.clda.com
CONTACT:
Media-Public Relations of Icoria, Inc.,
+1-919-425-2999
|
